PTPI Stock Overview A pharmaceutical company, focuses on men’s health therapeutics in the United States and internationally. More details
Risk Analysis + 1 more risk
See All Risk Checks {"enabled":false,"variant":{"name":"disabled","enabled":false},"ready":false,"error":null}
Capture your thoughts, links and company narrative
Petros Pharmaceuticals, Inc. Competitors Price History & Performance
Summary of share price highs, lows and changes for Petros Pharmaceuticals Historical stock prices Current Share Price US$0.24 52 Week High US$2.27 52 Week Low US$0.22 Beta 1.89 1 Month Change -30.43% 3 Month Change -11.21% 1 Year Change -85.00% 3 Year Change -98.55% 5 Year Change n/a Change since IPO -99.40%
Recent News & Updates See more updates
New major risk - Financial position Feb 11
Petros Pharmaceuticals, Inc. Announces Proprietary Technology Addressing the Rx-To-OTC Switch Self-Care Market Valued at over $38 Billion Annual Dec 18
New major risk - Share price stability Dec 17
Third quarter 2024 earnings: Revenues exceed analysts expectations while EPS lags behind Nov 15
It's Probably Less Likely That Petros Pharmaceuticals, Inc.'s (NASDAQ:PTPI) CEO Will See A Huge Pay Rise This Year Nov 13
Petros Pharmaceuticals, Inc. Announces Board Resignations Oct 07
Petros Pharmaceuticals, Inc., Annual General Meeting, Nov 20, 2024 Sep 20
Petros Pharmaceuticals, Inc. Executes Successful Initial Test for App Comprehension as Part of FDA Pathway for Over-the-Counter Access for STENDRA(R) (avanafil) Sep 11
Second quarter 2024 earnings: EPS and revenues exceed analyst expectations Aug 16
Petros Pharmaceuticals, Inc. Announces Results of First of Series of Pivotal Studies Aimed at Facilitating FDA-Approved OTC Access of STENDRA (Avanafil) for Consumers Jul 17
Petros Pharmaceuticals Successfully Completes AI-Integrated Formative Human Factors Study Demonstrating Positive Interaction with Web App Designed for STENDRA(R) (avanafil) OTC Switch May 30
First quarter 2024 earnings: EPS and revenues miss analyst expectations May 17
Petros Pharmaceuticals Receives Positive Response from Fda Following Recent Demonstration of Technology Component in Pursuit of Otc Status for Stendra(R) (Avanafil) Apr 17
New major risk - Shareholder dilution Apr 09
Full year 2023 earnings: EPS and revenues miss analyst expectations Apr 02
Petros Pharmaceuticals, Inc. Reports Positive Results in an Initial Cohort Two-Arm Self-Selection (Phase 2-Equivalent) Study for STENDRA (avanafil) as it Pursues OTC Status Apr 02
Insufficient new directors Feb 15
Petros Pharmaceuticals, Inc. Announces Successful Completion of the Initial Cohort of A Phase 2 Equivalent Self-Selection Study Jan 17
Petros Pharmaceuticals Successfully Completes Important Study in Effort to Make STENDRA(R) (avanafil) the First Erectile Dysfunction Medication to Achieve OTC Status Dec 12
Petros Pharmaceuticals, Inc., Annual General Meeting, Dec 29, 2023 Dec 01 Petros Pharmaceuticals, Inc. announced delayed 10-Q filing Nov 17
Petros Pharmaceuticals Announces to Develop Artificial Intelligence Technology for Phase 2 Equivalent Study for STENDRA(R) Oct 31
Petros Pharmaceuticals, Inc. Initiates Self-Selection (Phase 2-Equivalent) Study for STENDRA Oct 20
Petros Pharmaceuticals Announces Positive Outcomes in Label Comprehension Study for Potential Otc Stendra Label Oct 06
Second quarter 2023 earnings released: US$1.20 loss per share (vs US$0.88 loss in 2Q 2022) Aug 16 Petros Pharmaceuticals, Inc. announced that it expects to receive $15 million in funding Jul 14
First quarter 2023 earnings released: US$0.66 loss per share (vs US$0.084 loss in 1Q 2022) May 18
Third quarter 2022 earnings released: US$0.67 loss per share (vs US$0.17 loss in 3Q 2021) Nov 16
High number of new and inexperienced directors Nov 16
Petros Pharmaceuticals, Inc. Announces Expansion of FDA Labeling for Its Oral Erectile Dysfunction Drug, STENDRA Oct 28
Petros Pharmaceuticals, Inc., Annual General Meeting, Nov 29, 2022 Oct 13
Petros Pharmaceuticals GAAP EPS of -$0.10, revenue of $6.6M Aug 15
Second quarter 2022 earnings released: US$0.088 loss per share (vs US$0.22 loss in 2Q 2021) Aug 13
Petros Pharma shares more than triple in value after co to be taken private in $67.2M deal Jul 28
Petros Pharmaceuticals Receives Non-Compliance Notice from Nasdaq Jun 25
First quarter 2022 earnings released: US$0.008 loss per share (vs US$0.31 profit in 1Q 2021) May 18
Petros Pharmaceuticals, Inc. Announces They Will Be Pursuing the 505(B)(2) Pathway for Its Investigational Agent May 05
High number of new and inexperienced directors Apr 27
Petros Pharmaceuticals, Inc. Announces Positive Results of Over-The-Counter (Otc) Label Comprehension Study for Erectile Dysfunction Drug STENDRA Apr 20
Full year 2021 earnings released: US$0.82 loss per share (vs US$3.86 loss in FY 2020) Apr 02
Petros Pharmaceuticals Launches Two Self-Selection Studies for Erectile Dysfunction Drug Stendra (Avanafil) Jan 19
Petros Pharmaceuticals, Inc. announced that it has received $2.200023 million in funding Dec 29
Petros Pharmaceuticals, Inc. has completed a Follow-on Equity Offering in the amount of $5.299978 million. Dec 28
Petros Pharmaceuticals, Inc. announced that it expects to receive $2.200023 million in funding Dec 24
Petros Pharmaceuticals Announces Positive Over-the-Counter Label Comprehension Study Results for Erectile Dysfunction Drug STENDRA Dec 09
Petros Pharmaceuticals: Advancing Complementary Men's Health Therapeutics Dec 07
Third quarter 2021 earnings released: US$0.17 loss per share (vs US$0.96 loss in 3Q 2020) Nov 18
Second quarter 2021 earnings released: US$0.22 loss per share (vs US$1.68 loss in 2Q 2020) Aug 18
Petros Pharmaceuticals, Inc. Completes Pilot Label Comprehension Study to Initiate Process for Stendra® Prescription Erectile Dysfunction Medication to Achieve Designation as an Over-the-Counter Treatment Jul 15
Petros Pharmaceuticals, Inc.(NasdaqCM:PTPI) dropped from Russell Microcap Growth Index Jun 28
First quarter 2021 earnings released: EPS US$0.31 (vs US$1.77 loss in 1Q 2020) May 16
New 90-day low: US$3.22 Mar 04
Petros Pharmaceuticals Appoints Dr. Mohit Khera to Steering Committee Feb 19
Petros Pharmaceuticals, Inc. Appoints Mitchell Arnold to Serve as the Principal Financial Officer and Principal Accounting Officer Jan 28 Petros Pharmaceuticals, Inc. Announces Executive Changes Shareholder Returns PTPI US Pharmaceuticals US Market 7D -11.9% 1.2% 0.2% 1Y -85.0% 1.4% 23.1%
See full shareholder returns
Return vs Market: PTPI underperformed the US Market which returned 23.1% over the past year.
Price Volatility Is PTPI's price volatile compared to industry and market? PTPI volatility PTPI Average Weekly Movement 31.1% Pharmaceuticals Industry Average Movement 10.1% Market Average Movement 5.9% 10% most volatile stocks in US Market 18.3% 10% least volatile stocks in US Market 3.0%
Stable Share Price: PTPI's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: PTPI's weekly volatility has increased from 19% to 31% over the past year.
About the Company Petros Pharmaceuticals, Inc., a pharmaceutical company, focuses on men’s health therapeutics in the United States and internationally. It operates through two segments, Prescription Medications and Medical Devices. The company engages in the commercialization and development of Stendra, an PDE-5 inhibitor prescription medication for the treatment of erectile dysfunction (ED).
Show more Petros Pharmaceuticals, Inc. Fundamentals Summary How do Petros Pharmaceuticals's earnings and revenue compare to its market cap? PTPI fundamental statistics Market cap US$2.51m Earnings (TTM ) -US$19.85m Revenue (TTM ) US$4.02m
Earnings & Revenue Key profitability statistics from the latest earnings report (TTM) PTPI income statement (TTM ) Revenue US$4.02m Cost of Revenue US$1.11m Gross Profit US$2.92m Other Expenses US$22.76m Earnings -US$19.85m
Last Reported Earnings
Sep 30, 2024
Earnings per share (EPS) -1.98 Gross Margin 72.50% Net Profit Margin -493.45% Debt/Equity Ratio 232.5%
How did PTPI perform over the long term?
See historical performance and comparison
Company Analysis and Financial Data Status Data Last Updated (UTC time) Company Analysis 2025/02/12 22:55 End of Day Share Price 2025/02/12 00:00 Earnings 2024/09/30 Annual Earnings 2023/12/31
Data Sources The data used in our company analysis is from S&P Global Market Intelligence LLC . The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
Package Data Timeframe Example US Source * Company Financials 10 years Income statement Cash flow statement Balance sheet Analyst Consensus Estimates +3 years Forecast financials Analyst price targets Market Prices 30 years Stock prices Dividends, Splits and Actions Ownership 10 years Top shareholders Insider trading Management 10 years Leadership team Board of directors Key Developments 10 years
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more .
Analysis Model and Snowflake Details of the analysis model used to generate this report is available on our Github page , we also have guides on how to use our reports and tutorials on Youtube .
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github .
Analyst Sources Petros Pharmaceuticals, Inc. is covered by 1 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
Analyst Institution Nazibur Rahman Maxim Group
